OCUL - オキュラ―・セラピュ―ティクス (Ocular Therapeutix Inc.) オキュラ―・セラピュ―ティクス

 OCULのチャート


 OCULの企業情報

symbol OCUL
会社名 Ocular Therapeutix Inc (オキュラ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 オキュラー・セラピューティクス(Ocular Therapeutix Inc.)は独自のヒドロゲルプラットフォーム技術を使用して、目の病気と症状の治療法の開発・製造・商業化に従事するバイオ医薬品会社である。鉛管内使用のための主要製品候補であるDEXTENZA(デキサメタゾンインサート)は眼科手術後の眼の痛みおよび炎症の治療のための第III相臨床開発を完了した。OTX-TP(トラボプロストインサート)は、緑内障および高眼圧症の第III相臨床開発にある。その初期段階の資産には、中等度から重度の緑内障および高眼圧症の治療のための持続放出性トラボプロスト眼内注射、並びに網膜疾患の治療のための徐放性硝子体内注射であるOTX-TICが含まれる。これらの注射には、チロシンキナーゼ阻害剤であるOTX-TKIの開発、および延長された放出タンパク質ベースの抗血管内皮成長因子トラップであるRegeneronとの共同研究が含まれる。   オキュラ―・セラピュ―ティクスは眼疾患の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。ポリエチレン・グリコ―ルを基盤にしたヒドロゲルの点眼剤を開発。白内障切開部の閉鎖剤「リシュア」を販売するほか、白内障術後の眼炎症・疼痛のOTX-DP、緑内障と高眼圧症の治療薬OTX-TPの治験を行う。   Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
本社所在地 15 Crosby Drive Bedford MA 01730 USA
代表者氏名 Amarpreet Sawhney Amarpreet Sawhney
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 781-895-3235
設立年月日 38961
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.ocutx.com
nasdaq_url https://www.nasdaq.com/symbol/ocul
adr_tso
EBITDA EBITDA(百万ドル) -52.79000
終値(lastsale) 6.14
時価総額(marketcap) 236955997.48
時価総額 時価総額(百万ドル) 238.11380
売上高 売上高(百万ドル) 1.99800
企業価値(EV) 企業価値(EV)(百万ドル) 196.90980
当期純利益 当期純利益(百万ドル) -56.23800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ocular Therapeutix Inc revenues increased 8% to $988K. Net loss decreased 21% to $27.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling and Marketing - Balancing value decrease of 89% to $1.4M (expense) Stock-based Compensation in SGA decrease of 52% to $226K (expense).

 OCULのテクニカル分析


 OCULのニュース

   Biotech Takeovers Moved at Snail''s Pace in 2nd Quarter  2021/08/30 22:58:41 GuruFocus
Total value of deals was only $3.2 billion Related Stocks: CLVS , DNLI , AZN , MOR , BIIB , LLY , PFE , AMGN , MRK , ALNY , CRSP , ICPT , SRPT , MDGEF , ALBO , BLRX , OCUL ,
   Hydrogel Based Drug Delivery System Market is Expected to Create New Prospects in Near Future, Key Players -Bausch and Lomb, Medtronic, Ocular Therapeutix, Inc.  2021/08/27 12:20:47 OpenPR
New York, United States: Decisive Markets Insights portrays the Hydrogel Based Drug Delivery System MARKET in the best light with its business report. There are several factors at play in the market, which are discussed in depth in the report.
   Dumac, Inc. Buys Roblox Corp, XPeng Inc, Asana Inc, Sells Unity Software Inc, BigCommerce ...  2021/08/24 15:38:29 GuruFocus
Related Stocks: ASAN , PAGS , BAP , RBLX , XPEV , UPST , BABA , PATH , CRWD , U , BIGC , AFRM , BSM , PAM , OCUL ,
   Rubric Capital Management LP Buys Golar LNG, Arconic Corp, Karyopharm Therapeutics Inc, Sells ...  2021/08/17 18:38:09 GuruFocus
Related Stocks: OCUL , TROX , PTVE , PLYA , MORF , RDUS , GLNG , ARNC , KPTI , HMHC , CHMA , HSC , RXT , APO , MIC , THC , USFD , AEL ,
   Tiff Advisory Services Inc Buys Upstart Holdings Inc, Vanguard Financials ETF, Real Estate ...  2021/08/10 06:38:02 GuruFocus
Related Stocks: XLRE , XLU , UPST , VFH , BIGC , NARI , OCUL , VGK , XLK , SUSA ,
   Ocular Therapeutix Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases  2021/08/05 20:01:00 Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
   Dosing underway in Ocular Therapeutix''s early-stage trial of OTX-TKI for wet AMD  2021/07/29 12:48:20 Seeking Alpha
   Ocular Therapeutix to present clinical data at the 2021 ASCRS Annual Meeting  2021/07/23 13:29:50 Seeking Alpha
   Ocular Therapeutix To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting  2021/07/23 12:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held July 23-27, 2021 in Las Vegas, NV. At ASCRS, we will be presenting data on multiple programs we are advancing in the clinic as w
   Ocular Drug Delivery Global Market Size and Demand by: OCULAR THERAPEUTIX Inc, Alimera Sciences, Allergan PLC, EyeGate Pharma  2021/07/17 09:33:51 Tramways Monthly
Ocular Drug Delivery Market Report fulfills the Current as well as Future aspects and trends. The market study on Global Ocular Drug Delivery Market 2021- 2027 Research Report studies Deep analysis of the Ocular Drug Delivery Market primarily based upon factors on which the companies compete in the market, key trends, and segmentation analysis. Global Ocular []
   Ocular Therapeutix to Participate at Three Upcoming Investor Conferences  2021/05/26 12:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies Virtual Healthcare Conference Date: Tuesday, June 1, 2021 Analyst-hosted fireside chat: 4:00 PM ET The JMP Securities Life Sciences Conference Date: Wednesday, June 16, 2021 Analyst-hosted f
   Ocular Therapeut (OCUL) falls 0.43% for May 19  2021/05/19 22:00:26 Equities
Ocular Therapeut (NASDAQ: OCUL) shares fell -0.43% to end trading Wednesday at $13.93 per share - a net change of $-0.06. Shares traded between $14.07 and $13.64 throughout the day. 877945 shares of Ocular Therapeut exchanged hands. Visit Ocular Therapeuts profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Ocular Therapeut and to follow the companys latest updates, you can visit the companys profile page here: Ocular Therapeuts Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.
   Ocular Therapeutix Inc Shares Climb 2.8% Past Previous 52-Week High - Market Mover  2020/12/15 22:30:00 Kwhen Finance
Ocular Therapeutix Inc shares closed 2.8% higher than its previous 52 week high, giving the company a market cap of $1B. The stock is currently up 465.1% year-to-date, up 449.8% over the past 12 months, and up 160.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 1.2%. Trading Activity Trading volume this week was 42.8% higher than the 20-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at Infinity% higher than its 5-day moving average, 28.0% higher than its 20-day moving average, and 101.1% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio lags its average peer by -100.0% The company's performance over the last 1 year beats its average peer by -5791.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Ocular Therapeutix Inc Shares Climb 7.7% Past Previous 52-Week High - Market Mover  2020/12/14 22:30:00 Kwhen Finance
Ocular Therapeutix Inc shares closed 7.7% higher than its previous 52 week high, giving the company a market cap of $1B. The stock is currently up 424.8% year-to-date, up 410.6% over the past 12 months, and up 135.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 32.7% lower than the 20-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at Infinity% higher than its 5-day moving average, Infinity% higher than its 20-day moving average, and 86.8% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio lags its average peer by -100.0% The company's performance over the last 1 year beats its average peer by -4885.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Ocular Therapeutix Inc Shares Climb 1.9% Past Previous 52-Week High - Market Mover  2020/12/11 22:30:00 Kwhen Finance
Ocular Therapeutix Inc shares closed 1.9% higher than its previous 52 week high, giving the company a market cap of $1B. The stock is currently up 413.2% year-to-date, up 395.6% over the past 12 months, and up 110.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.0%. Trading Activity Trading volume this week was 25.4% lower than the 20-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at 3.8% higher than its 5-day moving average, 21.6% higher than its 20-day moving average, and 86.8% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio lags its average peer by -100.0% The company's performance over the last 1 year beats its average peer by -5452.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 オキュラ―・セラピュ―ティクス OCUL Ocular Therapeutix Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)